New funding mechanism aims to bring balance to the biomedical research (work)force

By -
by Chris Yarosh

This past March, the National Cancer Institute (NCI) announced a new funding mechanism designed to stabilize the biomedical research enterprise by creating new career paths for PhD-level scientists. That mechanism, called the NCI Research Specialist Award (R50), is now live. Applications (of which there will likely be many) for the R50 will be accepted beginning in January, with the first crop of directly-funded Research Specialists starting in October 2016. More details about the grant can be found in the newly released FOA.

Why is this a big deal? In recent years, there have been increased calls for reform of the biomedical enterprise. More people than ever hold PhDs, and professor positions (the traditional career goal of doctorate holders) are scarce. This leaves many young researchers trapped somewhere in the middle in postdoctoral positions, something we've talked about  before on this blog. These positions are still considered to be training positions, and without professor openings (or funding for independent labs), these scientists often seek industry positions or leave the bench altogether in lieu of finding academic employment.

On the flip side, modern academic labs are highly dependent on a constant stream of graduate students and postdocs to do the lion’s share of the research funded by principal investigator-level grants (R01s). This creates a situation where entire labs can turn over in relatively short periods of time, possibly diminishing the impact of crucial research programs.

But what if there was another way? That, in a nutshell, is the aim of the R50. By funding the salaries (but not the research costs) of PhD-level researchers, the R50 seeks to create opportunities for scientists to join established research programs or core facilities without having to obtain larger grants or academic appointments. This attempts to kill two birds with one stone: more jobs for PhDs, less turnover in labs already funded by other NCI grants.

This approach is not all roses, however. For one, this doesn’t change the fact that research funding has been flat or worse in recent years. Even with more stable staffing, the amount of research being completed will continue to atrophy. Moreover, the money for future R50s will need to come from somewhere, and it is possible that this will put additional strain on the NCI’s budget if overall R&D spending is not increased soon. Lastly, there are some concerns about how the R50 will work in practice. For example, Research Specialists will be able to move to other labs with NCI approval, but how will this actually play out? Will R50s really be pegged to their recipients, or will there be an implicit understanding that they are tied to the supporting labs/institutions?

It should be noted that this is only a trial period, and that full evaluation of the program will not be possible until awards are actually made. Still, this seems like a positive response to the forces currently influencing the biomedical research enterprise, and it will be interesting to see if and when the other NIH institutes give something like this a shot.

Comments

Post a Comment

Popular posts from this blog

2015 AAAS Science and Technology Policy Forum Summary

By -
I recently had the opportunity to attend the 2015 AAAS Science and Technology Policy Forum in Washington, D.C. This annual meeting brings together a range of academics and professionals to discuss the broad S&T policy landscape. Below are some of my takeaways from the meeting. I hope to have additional comments from other National Science Policy Group members up soon. By Chris Yarosh The talks and panels at the Forum encompassed a huge range of topics from the federal budget and the appropriations outlook to manufacturing policy and, of course, shrimp treadmills . My opinion of the uniting themes tying this gamut together is just that—my opinion— and should only be taken as such. That being said, the threads I picked on in many of the talks can be summarized by three C’s: cooperation, communication, and citizenship . First up, cooperation. Although sequestration’s most jarring impacts have faded, AAAS’s budget guru Matthew Hourihan warns that fiscal year 2016 could
Read more

AAAS Forum Take #2

By -
Another point of view of the AAAS Forum by Matthew Facciani: I have provided scientific testimony and met with some of my local legislators, but I’ve never had any formal exposure to science policy. I was really excited to hear about the AAAS Science & Technology Policy Forum to learn more about how scientists can impact policy. The information I absorbed at the conference was overwhelming, but incredibly stimulating. Some of the lectures discussed the budget cuts and the depressing barriers for achieving science policy. However, I felt there was definitely an atmosphere of optimism at the conference and it was focused on how we can create positive change. One of my favorite aspects of the conference were the discussions of how to effectively communicate science to non-scientists. Before we can even have discussions of funding, the general public needs to understand how science works and why basic science is so important. For example, science never proves anything with 100%
Read more

Dr. Sarah Cavanaugh discusses biomedical research in her talk, "Homo sapiens: the ideal animal model"

By -
Image
Biology and preclinical medicine rely heavily upon research in animal models such as rodents, dogs, and chimps. But how translatable are the findings from these animal models to humans? And what alternative systems are being developed to provide more applicable results while reducing the number of research animals? Image courtesy of PCRM Last Thursday, PSPG invited Dr. Sarah Cavanaugh from the Physicians Committee for Responsible Medicine to discuss these issues. In her talk entitled, “ Homo sapiens : the ideal animal model,” she emphasized that we are not particularly good at translating results from animal models into human patients. Data from the FDA says that 90% of drugs that perform well in animal studies fail when tested in clinical trials.  It may seem obvious, but it is important to point out that the biology of mice is not identical to human biology. Scientific publications have demonstrated important dissimilarities in regards to the pathology of inflammation , d
Read more